ArticleCancer journal (Sudbury, Mass.)
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
Article in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 78 citations in OpenAlex.
- Isolation and typing techniques for circulating tumor cells.Biomarker research · 2026Review
- Androgen Receptor Splice Variant-7 Expression Analysis in Circulating Tumor Cells: Methodology and Application of AdnaTest in Prostate Cancer Research.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Circulating tumor cells as biomarkers in melanoma: techniques, challenges, and clinical applications.Frontiers in cell and developmental biology · 2026Review
- Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.International journal of cancer · 2025Article
- A narrative review of the current state of circulating tumor cells in prostate cancer diagnostic.Hellenic urology · 2025Article
- Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review).Oncology letters · 2025Review
- Mitophagy related diagnostic biomarkers for coronary in-stent restenosis identified using machine learning and bioinformatics.Scientific reports · 2024Article
- Microfluidic Applications in Prostate Cancer Research.Micromachines · 2024Review
- Clinical Implementation of a Noninvasive, Multi-Analyte Droplet Digital PCR Test to Screen for Androgen Receptor Alterations.The Journal of molecular diagnostics : JMD · 2024Article
- EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients.Scientific reports · 2024Article
- Detection of circulating tumor cells by means of machine learning using Smart-Seq2 sequencing.Scientific reports · 2024Article
- Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma.Journal of personalized medicine · 2024Review
- Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications.Cancers · 2024Review
- Dissemination of Circulating Tumor Cells in Breast and Prostate Cancer: Implications for Early Detection.Endocrinology · 2024Review
- Review
- Craniofacial therapy: advanced local therapies from nano-engineered titanium implants to treat craniofacial conditions.International journal of oral science · 2023Review
- Article
- Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023Review
- Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Medical sciences (Basel, Switzerland) · 2023Review
- Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer.Clinical and translational science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Circulating tumor cell (CTC) number measured with the CellSearch assay is prognostic for survival in metastatic castration-resistant prostate cancer before and after therapy. Using a standard operating protocol for sample collection, processing, and analysis, we compared detection rates of CellSearch performed using US Food and Drug Administration-cleared methodology with a second positive selection assay, AdnaTest, and a nonselection polymerase chain reaction (PCR)-based (direct detection PCR [DDPCR]) assay in 55 blood samples from 47 men with progressive metastatic castration-resistant prostate cancer. AdnaTest requires processing within 4 hours of the draw and detects KLK3, PSMA, and EGFR transcripts in cells captured on magnetic beads. The DDPCR assay can be processed up to 7 days after a draw and detects KLK2, KLK3, HOXB13, GRHL2, and FOXA1 genes. AdnaTest and DDPCR were considered positive if at least 1 transcript was detected. AdnaTest detected CTCs in 34 samples (62%; 95% confidence interval [CI], 48%-75%), of which 23 (68%) had unfavorable CTC counts by CellSearch. A positive DDPCR result was seen in 38 cases (69%; 95% CI, 55%-81%), including 24 (63%) with unfavorable CellSearch CTC counts. CellSearch found unfavorable CTC counts in 25 samples (45%; 95% CI, 33%-58%). Sensitivities were similar between the AdnaTest and DDPCR assays, and both were more sensitive than CellSearch. Concordance probability estimates (possible values, 0.5-1.0) associating the biomarker result with survival were similar: 0.77 (SE, 0.07) for AdnaTest, 0.72 (SE, 0.08) for DDPCR, and 0.76 (SE, 0.06) for CellSearch. Overall detection rates between the AdnaTest and DDPCR assays were similar, and both were superior to CellSearch. The DDPCR assay required the lowest blood volume, least on-site processing, and longest stability for batch processing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.